Epidemiological Study in FRONtoTemporal Dementia

Launched by CENTOGENE GMBH ROSTOCK · Sep 30, 2021

Keywords

ClinConnect Summary

This clinical trial is studying Frontotemporal Dementia (FTD), a type of dementia that affects the brain and can change a person's behavior, personality, and ability to think. The researchers want to understand how often genetic factors (inherited traits) contribute to FTD in patients who have been diagnosed with this condition or who show signs of it. This is an important step in learning more about FTD and potentially improving future treatments.

To participate in this study, individuals need to be between 25 and 85 years old and either have a diagnosis of FTD or have symptoms that suggest they might have it. Participants will need to give their consent, which includes agreeing to genetic testing. While the study is currently active, it is not recruiting new participants at this time. Those who join can expect to contribute valuable information that may help researchers uncover the genetic causes of FTD, ultimately benefiting others affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
• • The participant is aged between 25 to 85 years
• • The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD